Overview of Pravafenix

Property	Description
Active ingredient	Pravastatin and Fenofibrate
Form	Hard capsule
Pharmacological class	Hypolipidemic Agent (Lipid-Modifying Agent)
Common use	Management of abnormal lipid levels (e.g., high cholesterol and high triglycerides)
Origin	Synthetic

Pravafenix is a prescription-only medication officially classified under the anatomical therapeutic chemical (ATC) code C10BA03 as a Hypolipidemic Agent. This synthetic drug is defined by its structure as a Fixed-Dose Combination product, consolidating two distinct active compounds into a single hard capsule intended for oral use. The concept of combining a statin with a fibrate is an established pharmacological approach.

Pravastatin and Fenofibrate: The Dual-Active Composition

The definitive composition of Pravafenix features two active ingredients with complementary actions: Pravastatin and Fenofibrate. Each hard capsule contains Pravastatin (the statin component) and Fenofibrate (the fibrate component), representing two separate pharmacological categories. The Pravastatin component belongs to the HMG-CoA reductase inhibitor class, focusing on inhibition of cholesterol biosynthesis.

The Fenofibrate component is a fibric acid derivative recognized for its primary action in accelerating the breakdown and clearance of triglyceride-rich particles. Statins and fibrates are recognized as two effective classes for lowering plasma lipids. The drug is designed to tackle both high cholesterol and high triglycerides effectively.

General Purpose: Targeting Mixed Hyperlipidaemia

The fundamental purpose of Pravafenix is the intensive, simultaneous modification of an abnormal lipid profile in adult patients as an adjunct to diet. This combination is generally positioned for patients diagnosed with mixed hyperlipidaemia where both elevated LDL cholesterol and high triglycerides contribute to overall cardiovascular risk.

By integrating the different mechanisms of effect, the combination aims to optimize levels of LDL cholesterol, elevated triglycerides, and low HDL cholesterol. This therapeutic approach is designed for patients whose lipid abnormalities require specific, simultaneous management of multiple lipid fractions.

Regulatory References

EMA Source

What side effects are possible with Pravafenix?

Pravafenix: Possible Side Effects and Safety Information

The regulatory safety profile for Pravafenix is structured around formally documented adverse reactions and specific usage constraints defined by government health authorities. Adverse effects are classified by the likelihood of their occurrence and grouped by the bodily systems they affect.

Official Adverse Reaction Frequencies

Adverse reactions are formally categorized based on official regulatory classifications:

Classification	Examples of Documented Effects
Common	Headache, dizziness, myalgia (muscle pain), and gastrointestinal symptoms (e.g., abdominal pain, nausea, flatulence).
Uncommon	Insomnia, visual disturbances, skin reactions (e.g., rash, pruritus), and neuropathy.
Rare	Pancreatitis, hepatitis, and severe muscle disorders like rhabdomyolysis.

System-Organ Classes and Serious Adverse Reactions

Adverse effects are documented across various System-Organ Classes, most notably Musculoskeletal and Connective Tissue Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders. The regulatory label identifies several rare events as clinically significant, including rhabdomyolysis and pancreatitis.

Population and Usage Safety Constraints

The use of Pravafenix is strictly defined by limitations documented in official labeling. The medication is contraindicated in patients with pre-existing conditions that increase risk, such as severe renal impairment, active liver disease, and unexplained, persistent elevation of liver transaminases. The safety profile also notes an increased risk of muscular adverse effects when co-administered with certain other medications. Furthermore, official documents note that elevations in liver enzymes may be observed during the initial phase of treatment.

Overdose and Emergency Response

The official regulatory documents state that clinical experience with Pravafenix overdosage, specifically involving Pravastatin and Fenofibrate, is limited. Documented manifestations of overdosage are typically non-specific, including nausea and vomiting associated with the statin component, and general gastrointestinal disturbances with the fibrate component.

Overdose Risk & Action	Regulatory Summary
Severe Outcomes	Overdosage carries the risk of severe systemic toxicity, notably rhabdomyolysis (severe muscle breakdown) which can lead to acute kidney injury, and significant hepatic injury (liver enzyme elevation).
Emergency Action	Individuals must seek immediate medical attention or call emergency services upon suspected overdosage. A poison control center should also be contacted for official guidance.
Antidote Status	No specific antidote is known for either the Pravastatin or Fenofibrate components, restricting management options.
Management Focus	Treatment is strictly symptomatic and supportive. Procedures such as gastric lavage or administration of activated charcoal may be utilized if the ingestion occurred recently.
Monitoring	Hospital observation may be necessary. Monitoring of laboratory values, particularly Creatine Kinase (CK) levels, is required to assess for potential muscle toxicity.

Overdosage management must address the pre-existing conditions of the patient, as regulatory documentation notes that the risk of severe toxicity is heightened in those with renal impairment, hepatic impairment, or those who are aged 70 years and older. The emphasis is on immediate care and specialized monitoring due to the known severe risks.

Therapeutic Uses of Pravafenix

Pravafenix supports the management of elevated cholesterol and specific fat levels in the blood, an approach that may assist in reducing the risk of certain cardiovascular concerns. It is generally used as an adjunctive treatment alongside dietary and lifestyle adjustments for individuals who have an inadequate response to those measures alone.

The medication is indicated for conditions such as primary hypercholesterolemia and mixed dyslipidemia. It is associated with a reduction in elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C), often referred to as 'bad' cholesterol, and triglycerides. For patients with a clinical history of heart concerns, Pravafenix is used to assist in the reduction of recurring myocardial infarction, the need for revascularization procedures, and the risk of stroke.

Quick Fact: Relief for Elevated Cholesterol Levels

Regulatory References

DailyMed prescribing information for pravastatin sodium

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Pravafenix

This information reflects the official eligibility and contraindication statements found in regulatory documents.

Populations Who Must NOT Use Pravafenix (Contraindications)

Pravafenix is contraindicated and must not be used by patients who have specific pre-existing conditions or are in certain physiological states. These include:

Children and Adolescents (under 18 years of age).
Pregnant and Breastfeeding Women.
Patients with Severe Hepatic Impairment, active liver disease, or unexplained persistent liver function abnormalities.
Patients with Moderate to Severe Renal Impairment (creatinine clearance < 60 ml/min).
Patients with Gallbladder Disease or certain types of pancreatitis.
Individuals with a personal history of myopathy (muscle damage) or rhabdomyolysis from previous statin or fibrate treatment.

Use Requiring Special Consideration

Some populations require special caution and evaluation before and during treatment:

Elderly Patients (over 70 years old).
Patients with Mild Hepatic or Renal Impairment.
Individuals with a history of hypothyroidism or heavy alcohol consumption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding co-administration due to documented interaction patterns involving the Pravastatin and Fenofibrate components.

Formal Prohibitions and Exposure-Altering Interactions

Co-administration with Systemic Fusidic Acid or other fibrates (e.g., Gemfibrozil) is strictly contraindicated due to the significantly increased, additive risk of severe muscle toxicity (myopathy/rhabdomyolysis). Clinically significant interactions occur with Ciclosporin (Cyclosporine), which inhibits drug transporters and increases the plasma concentration of the Pravastatin component.

Additive risk for muscle disorders is also documented with co-administration of Colchicine or Niacin (nicotinic acid). Furthermore, certain Macrolide Antibiotics (e.g., Erythromycin, Clarithromycin) are cited in regulatory labeling as increasing Pravastatin exposure via transporter inhibition.

Administration and Timing Constraints

Bile Acid Sequestrants (e.g., Colestyramine/Colestipol) reduce the bioavailability of Pravafenix through physical binding. To mitigate this effect, a mandatory timing rule requires that Pravafenix must be administered at least one hour before or four to six hours after the sequestrant. The Fenofibrate component must be administered with food to ensure optimal absorption and exposure. Caution is advised regarding co-consumption of substantial quantities of alcohol due to a documented additive risk of hepatotoxicity.

Population-Specific Notes

The risk of interaction-related muscle toxicity is heightened in patients with moderate to severe renal impairment and in the elderly (70 years old), according to official labeling.

Mechanism of Action

The mechanism of Pravafenix is based on the complementary, dual action of its two components, Pravastatin and Fenofibrate, each modulating distinct lipid metabolic pathways, resulting in a complementary modulation of the lipid profile.

Targeting Hepatic Cholesterol Synthesis

The Pravastatin component acts as a competitive inhibitor of the enzyme HMG-CoA reductase. This enzymatic blockade reduces the liver’s internal production of cholesterol, which subsequently triggers the liver to upregulate Low-Density Lipoprotein (LDL) receptors. This cascade ultimately enhances the catabolic clearance of circulating LDL cholesterol from the bloodstream, leading to a systemic modification of circulating lipoprotein concentrations.

Activating Nuclear Receptors for Triglyceride Catabolism

The second component, Fenofibrate, functions as an agonist for the PPARalpha nuclear receptor. Activation of this receptor leads to gene transcription that significantly increases the activity of lipoprotein lipase (LPL). The resulting physiological effect is the accelerated breakdown and clearance of triglyceride-rich VLDL and chylomicrons from the plasma, simultaneously altering High-Density Lipoprotein Cholesterol (HDL-C) concentrations.

Dual Mechanistic Synergy

These two mechanisms operate in parallel: one primarily modulating cholesterol synthesis and the other enhancing triglyceride catabolism. This distinct, coordinated action enables the simultaneous modulation of two distinct components of the lipid profile, which defines the full scope of the resulting lipid profile modulation.

Dosage and Administration Information

How to Use Pravafenix

Pravafenix is a fixed-dose combination medication intended for oral administration as part of a long-term treatment strategy for managing abnormal lipid levels. Its use is defined by established protocols concerning dosage, frequency, and specific patient conditions.

Official Administration Guidelines

The standard and sole recommended adult dose is one hard capsule per day, containing Pravastatin 40 mg and Fenofibrate 160 mg. This regimen is to be taken once daily. Standard practice specifies that the capsule should be administered during the evening meal to optimize the medication’s absorption characteristics. The hard capsule must be swallowed whole with water.

Procedural Context and Constraints

Treatment with Pravafenix is an adjunct to a continuous, prescribed lipid-lowering diet and appropriate physical activity. This lifestyle commitment must be established before initiating treatment and maintained throughout the course.

The therapy is intended for long-term use, but its continuation is contingent upon an adequate therapeutic response. Standard protocols require discontinuation if the patient's serum lipid values do not show the expected improvement within the first three months of treatment.

Usage is further constrained by specific patient populations. The medication is contraindicated for the pediatric population (under 18 years of age) and must not be administered to patients with moderate to severe renal impairment (defined as creatinine clearance <60 mL/min) or severe hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence of Lipid Profile Modification

Clinical trials have examined whether there was an improvement in the overall lipid profile for adult patients with mixed dyslipidaemia who are at high cardiovascular risk. Research has explored the drug's activity, which combines the effects of pravastatin (a statin) and fenofibrate (a fibrate). Studies have evaluated a potential reduction in key lipid markers.

One main Randomized Controlled Trial (RCT) involving patients at high risk showed a measured change in non-HDL-cholesterol levels over a 12-week period. Non-HDL-cholesterol levels were reduced on average by around 14% in patients taking the combination, compared with approximately 6% in patients taking pravastatin alone. A measured change in lipid markers was observed in 75% of participants.

Safety and Tolerability Profile

Safety data has been collected from studies involving adults. Studies documented a range of reported adverse events during the clinical trials, but research also investigated the time until reported changes in symptoms. However, studies suggest that co-administration with grapefruit juice may result in higher drug concentrations.

Risk assessment included monitoring for musculoskeletal and hepatobiliary disorders. The incidence of common adverse events was generally comparable between the combination and monotherapy groups. Research examined the drug's use in individuals with severe kidney issues, and findings have been reported regarding the drug's use in this population.

Comparative Research

Research has included comparative studies against older medications. Studies assessed the drug's use alongside other treatments and whether there was an association with a change in patient outcomes. The combination was evaluated against pravastatin monotherapy and simvastatin monotherapy in adults with mixed hyperlipidaemia.

Frequently Asked Questions (FAQ)

Common questions about Pravafenix (FAQ)

Q: How quickly can a person expect Pravafenix to start working?

Studies on the active component fenofibric acid indicate that the medicine reaches its highest concentrations in the blood within 6 to 8 hours after administration. When taken daily, a steady level of the medicine in the body is typically reached within 5 days.

Q: How long does it usually take to see the expected effects from Pravafenix?

According to regulatory documents, the initial effectiveness of the treatment is often evaluated by a healthcare professional based on lipid levels after starting the medicine. Lipid levels are often assessed following repeat determinations at intervals such as 4 to 8 weeks. Official guidance states that if a satisfactory response is not observed after 2 months, the medicine may be discontinued.

Q: Is Pravafenix a medicine that needs to be taken for a long time?

The official product information describes treatment with Pravafenix as a long-term therapy, intended to be used alongside a consistent diet and physical activity regimen. However, continuation of the medicine is contingent upon achieving a satisfactory therapeutic response as assessed by your healthcare provider.

Q: Can Pravafenix be used by people who have diabetes?

Official labeling notes that for patients with diabetes who have elevated chylomicronemia, improving glycemic control (blood sugar levels) is a consideration before initiating this therapy. It is also noted that the presence of diabetes may increase the risk of muscle-related side effects.

Q: What if I'm taking multiple medicines for the same condition—is Pravafenix compatible?

The combination of Pravafenix with other fibrates (like gemfibrozil) is strictly contraindicated by official documents because it significantly increases the risk of severe muscle toxicity. Caution is also advised regarding combining it with certain other lipid-lowering agents, such as Niacin, due to documented additive risks.

Q: Do older adults (seniors) need to take a special dose of Pravafenix?

The official product information for patients over 70 years old states that they require special caution and evaluation before and during treatment. The risk of muscle issues is heightened in this population, and dosing decisions are often based on an assessment of kidney function.

Q: Does Pravafenix require any special monitoring or regular blood tests?

Yes, regulatory documents recommend that a patient’s liver function should be monitored, including specific enzyme levels, at the start of therapy and periodically thereafter. Kidney function should also be monitored, particularly in individuals with pre-existing impairment.

Q: Is it common to have headaches when starting Pravafenix?

Clinical trial data lists headache as a common adverse reaction experienced by patients taking the individual components of Pravafenix. However, official documents do not specifically state if this side effect is confined only to the initial phase of treatment.

Q: Can Pravafenix affect liver enzyme levels?

Yes, official safety information states that elevations in liver enzymes may be observed when beginning treatment. For this reason, the medication is contraindicated (must not be used) in patients who have active liver disease or persistently elevated liver enzyme abnormalities.

Q: Is Pravafenix safe to use during pregnancy, according to official sources?

No. According to official product labeling, Pravafenix is contraindicated and must not be used by women who are pregnant or who may become pregnant. This is because the medication’s mechanism of action carries a descriptive risk of potential fetal harm.

Q: What happens if Pravafenix is taken with alcohol?

Official warnings advise that caution is necessary when co-consuming substantial quantities of alcohol. This warning is due to a documented additive risk of hepatotoxicity (damage to the liver) when the medicine and alcohol are combined.

Q: Can Pravafenix be used by people with kidney problems?

It is contraindicated (must not be used) for patients with moderate to severe renal impairment (kidney issues). Individuals with mild renal impairment require special caution and may need dose modifications for the pravastatin component.

Q: Why is Pravafenix often taken at a certain time of day?

Official administration instructions mandate that the medicine should be taken once daily during the evening meal. This specific timing is required to optimize the medication’s absorption characteristics in the body.

Q: Are there official warnings about combining Pravafenix with grapefruit products?

Official product documentation mentions that studies suggest co-administration with grapefruit juice may result in higher concentrations of the drug in the body. While this finding is noted in the research overview, it is not listed as a formal contraindication or major interaction warning in the regulatory sections.

Q: What is the risk classification of Pravafenix during breastfeeding?

According to official product information, Pravafenix is contraindicated and must not be used by women who are breastfeeding.

Q: Can Pravafenix be taken without food?

The official administration guidelines state the capsule must be administered during the evening meal. The regulatory documents specify that the fenofibrate component requires administration with food to ensure its optimal absorption.

Q: Does Pravafenix affect a person's ability to drive or operate machinery?

The official list of documented adverse effects includes both dizziness and visual disturbances. The product label advises caution, as these effects may affect a person’s ability to safely drive vehicles or operate machinery.

Q: How is Pravafenix eliminated from the body?

According to pharmacokinetic studies, the active metabolite, fenofibric acid, has an elimination half-life of approximately 20 hours. The medication and its metabolites are primarily eliminated from the body through the urine (about 60%) and the feces (about 25%).

Q: Is Pravafenix often used as a first-line treatment?

The therapy is indicated for use as an adjunct (an addition) to a diet and exercise program. It is also indicated for patients who have not achieved their treatment goals using a statin or fibrate alone. Official documents do not typically use the term 'first-line' when describing this medicine.

Q: Why is Pravafenix sometimes prescribed instead of other similar drugs?

Pravafenix is a fixed-dose combination that provides a complementary, dual action. It combines a statin to manage cholesterol with a fibrate to manage triglycerides, meaning the combination's design allows for the simultaneous modulation of two key components of the lipid profile.

Q: Are there different strengths or dosages available for Pravafenix?

The official product labeling defines the standard and sole recommended adult dose as one hard capsule containing the fixed combination of Pravastatin 40 mg and Fenofibrate 160 mg.

Q: Is Pravafenix a controlled substance?

According to the U.S. Drug Enforcement Administration (DEA) scheduling information, the active components, Pravastatin and Fenofibrate, are not listed as controlled substances.

Q: What are the main differences between Pravafenix and other drugs in the same class?

The key difference is its dual-active composition. It combines two separate pharmacological categories: a statin to primarily target cholesterol synthesis and a fibrate to enhance the breakdown of triglyceride-rich particles. This coordinated action provides a broad approach to modifying the patient's lipid profile.

Q: Does Pravafenix have a 'black box warning' in the United States?

The official U.S. labeling for Pravafenix does not contain a prominent Black Box Warning (a Boxed Warning). However, the label does include serious warnings regarding the potential risks of myopathy/rhabdomyolysis (muscle disorders) and hepatotoxicity (liver damage).

Q: Does Pravafenix have specific warnings for people with muscle conditions?

Yes. The medicine is contraindicated (must not be used) in people with a personal history of muscle damage (myopathy) or severe muscle breakdown (rhabdomyolysis) from previous treatment with a statin or a fibrate. The risk of muscle issues is also increased for the elderly and individuals with kidney impairment.

Q: Are there any specific lifestyle changes recommended when starting Pravafenix?

Treatment with Pravafenix is specifically intended as an adjunct (addition) to a continuous, physician-prescribed lipid-lowering diet and appropriate physical activity. Official documents state this commitment to a specialized diet and physical activity should be established before starting the medicine and maintained throughout the course.

How should Pravafenix be stored and disposed of?

How to Store and Dispose of Pravafenix?

The official labeling for Pravafenix (pravastatin/fenofibrate) specifies strict conditions for its storage and final disposal to maintain product integrity and ensure safety.

Required Storage Conditions

The medicine must be stored at a temperature below 25 C (77°F). Pravafenix hard capsules must be kept in the original container (blister pack and outer carton) to provide protection from moisture and light.

Safety and Disposal

For child safety, the medicine must be kept out of the sight and reach of children.

Disposal must adhere to environmental regulations. Unused or expired Pravafenix should not be disposed of into wastewater or general household trash. Instead, the product must be discarded according to local pharmaceutical waste regulations, often via an authorized drug take-back program or pharmacy collection point.

Pravafenix